Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
PaperCitations, authors & open-access status
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 641 citations, 2015 year and green oa status.
641
Citations
2015
Year
green
OA Status